Tuesday, 20 Mar 2018

You are here

Equal Cardiovascular Risks in Hypertensive Patients Treated with Selective and Nonselective NSAIDS

A Taiwanese study of 55,629 hypertensive patients shows no increased risk of  major cardiovascular events comparing outcomes of patients started on COX-2 selective NSAIDs compared with nonselective NSAIDs (including ibuprofen, diclofenac and naproxen).

This was a cohort study comparing hypertensive patients starting COX-2 selective NSAIDs or nonselective NSAIDs form Taiwan.  The outcomes of interest were major cardiovascular events of hospitalization for ischemic stroke, acute myocardial infarction, congestive heart failure, transient ischemic attack, unstable angina, or coronary revascularization. Patients were only followed for up to 4 weeks. 

Comparison groups included 2,749 eligible COX-2 selective NSAID users and 52,880 eligible nonselective NSAID users.

The HR of major cardiovascular events comparing COX-2 selective NSAIDs to nonselective NSAIDs after adjusting for baseline and time-varying covariates was 1.07 (95% CI, 0.65-1.74). The results were the same when comparing celecoxib to to diclofenac (HR, 1.17; 95% CI, 0.61-2.25), ibuprofen (HR, 1.36; 95% CI, 0.58-3.18), or naproxen (HR, 0.75; 95% CI, 0.23-2.44). There was an increased risk with COX-2 selective NSAIDs, however, when comparing COX-2 to mefenamic acid (HR, 2.11; 95% CI, 1.09-4.09).

These data mirror that seen in the recent completed PRECISION study. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Repeat Malignancy Unlikely with Biologic Therapy

Research from the Danish biologics registry shows that the use of a biologic in patients with a history of a primary cancer does not increase the risk of a second malignant neoplasm (SMN) or mortality in rheumatoid arthritis (RA) patients.

They analyzed 15,286 RA patients in the DANBIO Register between 2000–2011 and found 1678 with a primary cancer.  The majority (1203) did not use biologics after. 

Opportunistic Infections in RA Rare with Biologics

The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis has studied nearly 20,000 patients and observed that there is no substantially different risk of opportunistic infections between different biologics. 

Biologics in Pregnancy: Are They Safe?

Exposure to biologic therapies among women with autoimmune diseases was not associated with increased risks of preterm delivery or having small for gestational age babies, a population-based Canadian study found.

DSB – Safety Updates & Drug Shortages – March 2018

This edition of RheumNow's Drug Safey Bulletin includes drug safety news, FDA updates, FDA safety labeling changes and reported drug shortages. 

Steroid Use During Rheumatoid Pregnancies

Pregnant women (n=254) with rheumatoid arthritis who enrolled in the MotherToBaby Autoimmune Diseases in Pregnancy Study  and who were taking oral glucocorticoids were studied.